$2.45
+0.13 (+5.60%)
Open$2.37
Previous Close$2.32
Day High$2.47
Day Low$2.33
52W High$7.80
52W Low$1.31
Volume—
Avg Volume1.00M
Market Cap171.07M
P/E Ratio—
EPS$-1.30
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,490.6% upside
Current
$2.45
$2.45
Target
$38.97
$38.97
$29.17
$38.97 avg
$44.78
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 77.00M | 76.19M | 65.35M |
| Net Income | -1,399,615 | -1,371,226 | -1,459,846 |
| Profit Margin | -1.8% | -1.8% | -2.2% |
| EBITDA | -1,495,155 | -1,465,448 | -1,363,438 |
| Free Cash Flow | -1,111,108 | -1,336,142 | -1,081,347 |
| Rev Growth | +16.0% | +7.1% | -1.4% |
| Debt/Equity | 0.13 | 0.12 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |